Literature DB >> 20699241

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Daniel Aletaha1, Tuhina Neogi, Alan J Silman, Julia Funovits, David T Felson, Clifton O Bingham, Neal S Birnbaum, Gerd R Burmester, Vivian P Bykerk, Marc D Cohen, Bernard Combe, Karen H Costenbader, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Johanna M W Hazes, Kathryn Hobbs, Tom W J Huizinga, Arthur Kavanaugh, Jonathan Kay, Tore K Kvien, Timothy Laing, Philip Mease, Henri A Ménard, Larry W Moreland, Raymond L Naden, Theodore Pincus, Josef S Smolen, Ewa Stanislawska-Biernat, Deborah Symmons, Paul P Tak, Katherine S Upchurch, Jirí Vencovsky, Frederick Wolfe, Gillian Hawker.   

Abstract

OBJECTIVE: The 1987 American College of Rheumatology (ACR; formerly the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticised for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA.
METHODS: A joint working group from the ACR and the European League Against Rheumatism developed, in three phases, a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/or erosive disease--this being the appropriate current paradigm underlying the disease construct 'RA'.
RESULTS: In the new criteria set, classification as 'definite RA' is based on the confirmed presence of synovitis in at least one joint, absence of an alternative diagnosis better explaining the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in four domains: number and site of involved joints (range 0-5), serological abnormality (range 0-3), elevated acute-phase response (range 0-1) and symptom duration (two levels; range 0-1).
CONCLUSION: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features. This will refocus attention on the important need for earlier diagnosis and institution of effective disease-suppressing therapy to prevent or minimise the occurrence of the undesirable sequelae that currently comprise the paradigm underlying the disease construct 'RA'.

Entities:  

Mesh:

Year:  2010        PMID: 20699241     DOI: 10.1136/ard.2010.138461

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  1022 in total

1.  Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis.

Authors:  Alvin Yee; Tyler Webb; Andrea Seaman; Maria Infantino; Francesca Meacci; Mariangela Manfredi; Maurizio Benucci; Gabriella Lakos; Ennio Favalli; Tommaso Schioppo; Tommaso Shioppo; Pier-Luigi Meroni; Michael Mahler
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Cartilage quality in rheumatoid arthritis: comparison of T2* mapping, native T1 mapping, dGEMRIC, ΔR1 and value of pre-contrast imaging.

Authors:  Christian Buchbender; Axel Scherer; Patric Kröpil; Birthe Körbl; Michael Quentin; Dorothea Ch Reichelt; Rotem S Lanzman; Christian Mathys; Dirk Blondin; Bernd Bittersohl; Christoph Zilkens; Matthias Hofer; Hans-Jörg Wittsack; Matthias Schneider; Gerald Antoch; Benedikt Ostendorf; Falk Miese
Journal:  Skeletal Radiol       Date:  2011-09-20       Impact factor: 2.199

Review 3.  RA in 2011: Advances in diagnosis, treatment and definition of remission.

Authors:  Gerd R Burmester
Journal:  Nat Rev Rheumatol       Date:  2012-01-10       Impact factor: 20.543

4.  Rheumatoid arthritis: Why wait? Explaining delays in seeking therapy for early arthritis.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini
Journal:  Nat Rev Rheumatol       Date:  2012-03-06       Impact factor: 20.543

5.  Multiple arthritis: three in one.

Authors:  Celia Coelho Henriques; Filipa Lourenço; Begoña Lopéz; António Panarra; Nuno Riso
Journal:  BMJ Case Rep       Date:  2012-03-08

6.  Clinical guidelines: Classifying RA the 2010 way--what does it mean for the clinic?

Authors:  Annette H M van der Helm-van Mil
Journal:  Nat Rev Rheumatol       Date:  2011-01       Impact factor: 20.543

7.  The relationship between disease activity and depressive symptoms severity and optimism--results from the IMPROVED study.

Authors:  L Heimans; K V C Wevers-de Boer; K Visser; H K Ronday; G M Steup-Beekman; M van Oosterhout; T W J Huizinga; E J Giltay; R C van der Mast; C F Allaart
Journal:  Clin Rheumatol       Date:  2013-07-24       Impact factor: 2.980

8.  Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients.

Authors:  Akbar Soleimani; Zahra Mobedi; Maryam Al-E-Rasul; Abolghasem Sharifi; Abdolrahim Kazemi Vardanjani
Journal:  J Clin Diagn Res       Date:  2017-03-01

9.  Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib.

Authors:  Diana S Novikova; Helen V Udachkina; Eugenia I Markelova; Irina G Kirillova; Anna S Misiyuk; Natalia V Demidova; Tatiana V Popkova
Journal:  Rheumatol Int       Date:  2019-05-03       Impact factor: 2.631

10.  Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study.

Authors:  Yvonne C Lee; Clifton O Bingham; Robert R Edwards; Wendy Marder; Kristine Phillips; Marcy B Bolster; Daniel J Clauw; Larry W Moreland; Bing Lu; Alyssa Wohlfahrt; Zhi Zhang; Tuhina Neogi
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.